AzurRx BioPharma (NASDAQ:AZRX) had its price objective reduced by HC Wainwright from $5.00 to $2.00 in a report released on Wednesday morning, BenzingaRatingsTable reports. They currently have a buy rating on the stock.
Separately, Roth Capital reissued a buy rating on shares of AzurRx BioPharma in a report on Friday, January 24th. Five equities research analysts have rated the stock with a buy rating, The stock currently has a consensus rating of Buy and an average target price of $4.67.
AzurRx BioPharma stock traded up $0.01 during midday trading on Wednesday, hitting $0.55. The company’s stock had a trading volume of 63,496 shares, compared to its average volume of 209,942. AzurRx BioPharma has a 1-year low of $0.37 and a 1-year high of $3.10. The company has a market cap of $14.46 million, a price-to-earnings ratio of -0.60 and a beta of 2.12. The company has a 50-day moving average price of $0.73 and a two-hundred day moving average price of $0.84.
AzurRx BioPharma Company Profile
AzurRx BioPharma, Inc researches and develops non-systemic biologics for the treatment of patients with gastrointestinal disorders. Its product pipeline consists of two therapeutic proteins under development, including MS1819, a yeast derived recombinant lipase, which is in Phase II clinical trial for the treatment of exocrine pancreatic insufficiency associated with chronic pancreatitis and cystic fibrosis; and AZX1101, an enzymatic combination of bacterial origin for the prevention of hospital-acquired infections and antibiotic-associated diarrhea.
Further Reading: What are the FAANG Stocks?
Receive News & Ratings for AzurRx BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AzurRx BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.